APM logo

Aptorum Group Limited (APM) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

18 December 2018

Indexes:

Not included

Description:

Aptorum Group Limited is a biopharmaceutical company focused on developing innovative treatments for various diseases. They work on new drugs and therapies, particularly in areas like metabolic and infectious diseases, aiming to improve patient outcomes and address unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Dec 20, 2024

Recent quarterly earnings:

Apr 30, 2024

Recent annual earnings:

Apr 30, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 23, 2023

Analyst ratings

Recent major analysts updates

07 Oct '22 HC Wainwright & Co.
Buy
02 Apr '19 China Renaissance
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

5 Investors Betting Big on Aptorum (APM) Group
5 Investors Betting Big on Aptorum (APM) Group
5 Investors Betting Big on Aptorum (APM) Group
APM
InvestorPlace06 March 2024

Clinical-stage biopharmaceutical firm Aptorum (NASDAQ: APM ) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what's helping APM stock rocket higher.

Why Is Aptorum (APM) Stock Up 346% Today?
Why Is Aptorum (APM) Stock Up 346% Today?
Why Is Aptorum (APM) Stock Up 346% Today?
APM
InvestorPlace06 March 2024

Aptorum (NASDAQ: APM ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group. This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete.

Why Is Aptorum (APM) Stock Down 16% Today?
Why Is Aptorum (APM) Stock Down 16% Today?
Why Is Aptorum (APM) Stock Down 16% Today?
APM
InvestorPlace08 May 2023

Aptorum (NASDAQ: APM ) stock is falling on Monday after the company received a delisting notice from the Nasdaq Stock Market LLC. The reason given for the delisting notice is Aptorum failing to maintain proper equity to remain on The Nasdaq Global Market.

Why Is Aptorum (APM) Stock Up 166% Today?
Why Is Aptorum (APM) Stock Up 166% Today?
Why Is Aptorum (APM) Stock Up 166% Today?
APM
InvestorPlace03 May 2023

Aptorum (NASDAQ: APM ) stock is climbing higher on Wednesday despite a lack of news from the clinical-stage biopharmaceutical company. However, trading of APM stock is taking off today with more than 1 million shares on the move.

Aptorum Group shares double after merger plans, earnings delight investors
Aptorum Group shares double after merger plans, earnings delight investors
Aptorum Group shares double after merger plans, earnings delight investors
APM
Proactive Investors03 May 2023

Aptorum Group saw its market capitalization double following a busy week where the biopharmaceutical firm released its latest results and announced a merger plan. Shares of the Nasdaq-listed company were up over 109% by midday Wednesday at US$5.85.

FAQ

  • What is the primary business of Aptorum Group Limited?
  • What is the ticker symbol for Aptorum Group Limited?
  • Does Aptorum Group Limited pay dividends?
  • What sector is Aptorum Group Limited in?
  • What industry is Aptorum Group Limited in?
  • What country is Aptorum Group Limited based in?
  • When did Aptorum Group Limited go public?
  • Is Aptorum Group Limited in the S&P 500?
  • Is Aptorum Group Limited in the NASDAQ 100?
  • Is Aptorum Group Limited in the Dow Jones?
  • When was Aptorum Group Limited's last earnings report?
  • When does Aptorum Group Limited report earnings?
  • Should I buy Aptorum Group Limited stock now?

What is the primary business of Aptorum Group Limited?

Aptorum Group Limited is a biopharmaceutical company focused on developing innovative treatments for various diseases. They work on new drugs and therapies, particularly in areas like metabolic and infectious diseases, aiming to improve patient outcomes and address unmet medical needs.

What is the ticker symbol for Aptorum Group Limited?

The ticker symbol for Aptorum Group Limited is NASDAQ:APM

Does Aptorum Group Limited pay dividends?

No, Aptorum Group Limited does not pay dividends

What sector is Aptorum Group Limited in?

Aptorum Group Limited is in the Healthcare sector

What industry is Aptorum Group Limited in?

Aptorum Group Limited is in the Biotechnology industry

What country is Aptorum Group Limited based in?

Aptorum Group Limited is headquartered in United Kingdom

When did Aptorum Group Limited go public?

Aptorum Group Limited's initial public offering (IPO) was on 18 December 2018

Is Aptorum Group Limited in the S&P 500?

No, Aptorum Group Limited is not included in the S&P 500 index

Is Aptorum Group Limited in the NASDAQ 100?

No, Aptorum Group Limited is not included in the NASDAQ 100 index

Is Aptorum Group Limited in the Dow Jones?

No, Aptorum Group Limited is not included in the Dow Jones index

When was Aptorum Group Limited's last earnings report?

Aptorum Group Limited's most recent earnings report was on 30 April 2024

When does Aptorum Group Limited report earnings?

The next expected earnings date for Aptorum Group Limited is 20 December 2024

Should I buy Aptorum Group Limited stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions